DexCom stock reports 13.1 percent revenue growth at USD 86.62

Published on 09/28/2026 at 13:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DexCom stock delivered USD 0.70 adjusted EPS in Q2 2026, beating USD 0.61 consensus. Truist raised its target to USD 102.00 on September 17.

Fotorealistischer CGM-Sensor-Patch am Arm, klinisches Umfeld, Medizintechnik — Dexcom Inc. zeigt fotorealistischen CGM-Sensor am Unterarm für Anleger mit ISIN US2521311074 Medizintechnik, Illustration mit AI erstellt.

DexCom stock (ISIN US2521311074) closed at USD 86.62 on Nasdaq on September 25, 2026, down 0.97 percent from the prior close. The latest quarterly report showed revenue of USD 1.31 billion, up 13.1 percent year over year, keeping operating growth at the center of the valuation debate.

Quarterly revenue climbs 13.1 percent

According to MarketBeat on September 25, 2026, DexCom reported USD 0.70 adjusted EPS for the quarter, above the USD 0.61 consensus estimate. Revenue reached USD 1.31 billion against expectations of USD 1.29 billion, a USD 0.02 billion beat that reinforces the importance of execution as the company expands continuous glucose monitoring adoption.

DexCom develops real-time continuous glucose monitoring systems, including the Dexcom G7 and Stelo products. The business combines wearable sensors, software and data services, giving revenue growth a direct link to sensor adoption and recurring replacement demand.

Truist lifts target to USD 102.00

Yahoo Finance reported on September 17, 2026, that Truist Securities raised its DexCom price target from USD 93.00 to USD 102.00 while maintaining a Buy rating. The new target stands 17.72 percent above the September 25 closing price, while the average target listed by Investing.com was USD 94.48 on September 28, 2026.

The comparison also shows why the stock's next move depends on more than the latest earnings beat. DexCom delivered double-digit revenue growth, but the September 25 close remained USD 5.97 below the 52-week high of USD 92.59, leaving the market to weigh growth against valuation.

Stock stays below its yearly high

DexCom traded between USD 86.36 and USD 87.64 on September 25, 2026, with volume of 1,891,023 shares. Its 52-week range was USD 54.11 to USD 92.59, and the company had a market capitalization of USD 32.7 billion on that date.

For investors, the central checkpoint is the gap between operating delivery and expectations. Q2 revenue growth of 13.1 percent and adjusted EPS of USD 0.70 provide the latest quantified evidence, while the target revisions show that analysts are assigning value to continued execution rather than to a single product launch.